Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Minimally invasive fibroid treatment fares well in multicenter trial

27.02.2008
A new multicenter trial found that uterine artery embolization (UAE) is a good alternative to hysterectomy in women with symptomatic fibroids. The findings of the Embolisation versus Hysterectomy (EMMY) Trial appear in the March issue of the journal Radiology.

“After two years, patients who had undergone UAE reported health-related quality of life equal to that of women who had undergone hysterectomy,” said study co-author Jim A. Reekers, M.D., Ph.D., an interventional radiologist at Academic Medical Centre in Amsterdam, Netherlands.

Uterine fibroids are benign growths of the muscle inside the uterus. According to the National Institutes of Health, at least 25 percent of women in the U.S. age 25 to 50 suffer from symptomatic uterine fibroids. Fibroid symptoms can include excessive menstrual bleeding, enlarged uterine size, frequent urination, pelvic pressure or pain and infertility.

According to the National Women’s Health Information Center, fibroids are the primary reason for surgical removal of the uterus, accounting for approximately one-third of the 600,000 hysterectomies performed annually in the U.S.

UAE is a minimally invasive fibroid treatment in which catheters are placed in each of the two uterine arteries, and small particles are injected to block the arterial branches that supply blood to the fibroids. The fibroid tissue dies, the masses shrink and, in most cases, symptoms are relieved. UAE requires only a local anesthetic and has a shorter recovery period than hysterectomy.

“UAE has a number of benefits compared to hysterectomy,” said co-author Wouter J.K. Hehenkamp, M.D., gynecology resident at Academic Medical Centre. “With UAE, there is a faster recovery time, a shorter hospital stay and, most importantly, the uterus is not removed.”

For the EMMY trial, 177 women with uterine fibroids and heavy menstrual bleeding scheduled to undergo hysterectomy were randomly assigned to undergo UAE (88 women) or hysterectomy (89 women). During a 24-month follow-up period, 20 percent of women who had undergone embolization in the trial subsequently underwent hysterectomy due to insufficient symptomatic relief. Over the same period, health-related quality of life (HRQOL) was measured six times for all women in the trial with a series of scientifically validated questionnaires, which assessed various physical, mental and functional components contributing to quality of life, as well as overall satisfaction with the treatment.

Results showed that HRQOL improved significantly in all patients six months after treatment, except in the defecation distress inventory, which improved significantly in the UAE patients at six-month follow-up, but not the hysterectomy patients. Six weeks after treatment, the UAE patients also scored significantly higher scores on the physical component summary, which measured factors related to physical function.

After 24 months, no HRQOL differences were observed between the two groups, but while more than 90 percent of patients in both groups were at least moderately satisfied with the treatment they received, the hysterectomy patients reported a higher level of overall satisfaction. This may be attributable to the fact that they no longer experienced menstrual cycles or worried that their symptoms would recur. However, previous studies lasting several years have shown that it is rare for treated fibroids to regrow or for new fibroids to develop after UAE.

“For those women seeking absolute certainty of being asymptomatic after treatment, I would recommend a hysterectomy,” Dr. Reekers said. “But for women who wish to retain their uterus and who desire a fast recovery, I would definitely recommend UAE.”

Maureen Morley | EurekAlert!
Further information:
http://www.rsna.org

More articles from Health and Medicine:

nachricht Remdesivir prevents MERS coronavirus disease in monkeys
14.02.2020 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Recent advances in addressing tuberculosis give hope for future
12.02.2020 | NIH/National Institute of Allergy and Infectious Diseases

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Freiburg researcher investigate the origins of surface texture

Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.

Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...

Im Focus: Skyrmions like it hot: Spin structures are controllable even at high temperatures

Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices

The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...

Im Focus: Making the internet more energy efficient through systemic optimization

Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.

Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.

Im Focus: New synthesis methods enhance 3D chemical space for drug discovery

After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.

"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.

Im Focus: Quantum fluctuations sustain the record superconductor

Superconductivity approaching room temperature may be possible in hydrogen-rich compounds at much lower pressures than previously expected

Reaching room-temperature superconductivity is one of the biggest dreams in physics. Its discovery would bring a technological revolution by providing...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

Gold nanoclusters: new frontier for developing medication for treatment of Alzheimer's disease

17.02.2020 | Life Sciences

Artificial intelligence is becoming sustainable!

17.02.2020 | Information Technology

Catalyst deposition on fragile chips

17.02.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>